Evidence map›Paper›PMID 35723276›Full record

ArticleNeuro-oncology2022

FRK inhibits glioblastoma progression via phosphorylating YAP and inducing its ubiquitylation and degradation by Siah1.

Yan Wang, Kai Wang, Jiale Fu, Yu Zhang, Yufei Mao, Xu Wang, Xiang Wang, Rutong Yu, Xiuping Zhou

Open access · bronzeAbstract read
In one paragraph

Article in Neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Targeting ubiquitination in disease and therapy.Signal transduction and targeted therapy · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yan WangInstitute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, China.ORCID 0000-0002-4133-2269
Kai WangInstitute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, China.ORCID 0000-0001-7757-3243
Jiale FuInstitute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, China.ORCID 0000-0002-9596-5758
Yu ZhangInstitute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, China.ORCID 0000-0003-3737-5423
Yufei MaoInstitute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, China.ORCID 0000-0001-5511-1822
Xu WangInstitute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, China.ORCID 0000-0002-8778-0235
Xiang WangInstitute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, China.ORCID 0000-0003-3880-1025
Rutong YuInstitute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Xiuping ZhouInstitute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, China.ORCID 0000-0002-6663-8168
Xuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe previously report that yes-associated protein (YAP), the core downstream effector of Hippo pathway, promotes the malignant progression of glioblastoma (GBM). However, although classical regulatory mechanisms of YAP are well explored, how YAP is modulated by the Hippo-independent manner remains poorly understood. Meanwhile, the nonreceptor tyrosine kinase Fyn-related kinase (FRK), which exhibits low expression and possesses tumor suppressor effects in GBM, is reported to be involved in regulation of protein phosphorylation. Here, we examined whether FRK could impede tumor progression by modulating YAP activities.

methodsHuman GBM cells and intracranial GBM model were used to assess the effects of FRK and YAP on the malignant biological behaviors of GBM. Immunoblotting and immunohistochemistry were used to detect the expression of core proteins in GBM tissues. Co-immunoprecipitation, proximity ligation assay, luciferase assay and ubiquitination assay were utilized to determine the protein-protein interactions and related molecular mechanisms.

resultsThe expression levels of FRK and YAP were inversely correlated with each other in glioma tissues. In addition, FRK promoted the ubiquitination and degradation of YAP, leading to tumor suppression in vitro and in vivo. Mechanistically, FRK interacted with and phosphorylated YAP on Tyr391/407/444, which recruited the classical E3 ubiquitin ligase Siah1 to catalyze ubiquitination and eventually degradation of YAP. Siah1 is required for YAP destabilization initiated by FRK.

conclusionsWe identify a novel mechanism by which FRK orchestrates tumor-suppression effect through phosphorylating YAP and inducing its ubiquitination by Siah1. FRK-Siah1-YAP signaling axis may serve as a potential therapeutic target for GBM treatment.

Indexed as

GlioblastomaGliomaNeoplasm ProteinsProtein-Tyrosine KinasesCell Line, TumorCell ProliferationHumansSeven in Absentia ProteinsUbiquitinationYAP-Signaling ProteinsFRK protein, humanNeoplasm ProteinsProtein-Tyrosine KinasesSeven in Absentia ProteinsYAP1 protein, humanYAP-Signaling ProteinsFRKGBMSiah1ubiquitinationYAP

Identifiers

PMID35723276
PMCPMC9713521
OpenAlexW4283169240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.